Syndax unveils new pipeline assets SNDX-4321 and SNDX-62122
Syndax Pharmaceuticals unveiled two new pipeline assets, a mutant-selective EGFR inhibitor and a next-generation menin inhibitor, and confirmed the Phase 2 trial of axatilimab is on track for data in 4Q26.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day